MedTrace Logo

An Open-label Study With NVC-001 in Patients With LMNA-related Dilated Cardiomyopathy (SUNBEAM-LMNA)

NCT07606274 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2026-05-26

No results posted yet for this study

Summary

This study will be conducted to evaluate the safety and tolerability, and assess exploratory efficacy of NVC-001 in adults participants with LMNA-Related Dilated Cardiomyopathy.

Conditions

  • LMNA-Related Dilated Cardiomyopathy

Interventions

GENETIC

NVC-001 - Low Dose

Solution for intravenous infusion

GENETIC

NVC-001 - Intermediate Dose

Solution for intravenous infusion

GENETIC

NVC-001 - High Dose

Solution for intravenous infusion

Sponsors & Collaborators

  • Nuevocor Pte. Ltd.

    lead INDUSTRY

Principal Investigators

  • Monica Shah, MD · Nuevocor Pte. Ltd.

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-08
Primary Completion
2030-03-31
Completion
2030-03-31
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07606274 on ClinicalTrials.gov